Glycosphingolipids as Therapeutic Targets and Biomarkers of Lupus Nephritis
Abstract
All urine and serum samples for the full biomarker study in lupus nephritis patients that have responded and failed therapy have been identified and collected. Prior to beginning the full study, we tested/streamlined the workflow and identified putative lipid/protein candidates in a pilot study among the full study patients that had flare and non-flare urine samples. We also collected all the renal biopsies and are currently performing the MALDI/FTICR analyses for correlating renal lipid expression with clinical disease measures. We completed the backcrossing of the Neu1 knockout from the C57BL/6 mice to the lupus mouse strain B6.SLE1/2/3 and are breeding to obtain sufficient numbers of mice for the genetic study analyzing the effects of reducing NEU1 levels on disease development. To identify mechanisms by which NEU-mediated GSL catabolism impacts renal function and dysfunction in lupus, additional studies were performed on mesangial cells from mice in our proposed studies. Results include demonstrating that 1) that NEU activity mediates IL-6 production in mesangial cells, 2) NEU1/3 expression co-localizes with renal IgG deposition, and 3) mesangial cells from Neu1 knockout mice have reduced NEU activity and produce significantly reduced levels of IL-6 compared to Neu wild-type.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2017
- Accession Number
- AD1078492
Entities
People
- Tamara K Nowling
Organizations
- Medical University of South Carolina